IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...

Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...

Axonics' R20 system is designed to be implanted for at least 20 years. It needs to be recharged for only one hour every six to 10 months—essentially, just twice a year—compared to previous generations ...

Sales of the R20 neurostimulator have already begun in Canada, and Axonics said in this week’s announcement that it’s aiming to expand that rollout southward to the U.S. within the next few months.

Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...

Boston Scientific Corporation (NYSE:BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $71 in cash per share, representing an enterprise value of approximately $3.4 billion and an equity value ...

Germany's special fund for infrastructure has so far failed to reach its targets on how much to disburse, a 383-page finance ministry report due to be published this week shows, ‌newspaper ...

Never miss a trade again with the fastest news alerts in the world! This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday. Want the ...